Fatty liver and chronic kidney disease: Novel mechanistic insights and therapeutic opportunities

Diabetes Care

Volumn 39, Issue 10, 2016, Pages 1830-1845

  Musso, Giovanni ^a   Cassader, Maurizio ^b   Cohney, Solomon ^c   De Michieli, Franco ^b   Pinach, Silvia ^b   Saba, Francesca ^b   Gambino, Roberto ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1; CHEMOKINE; CHEMOKINE RECEPTOR CCR2; CHOLESTEROL ESTER TRANSFER PROTEIN; CRYOPYRIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR 21; GALECTIN 3; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INCRETIN; INSULIN RECEPTOR SUBSTRATE 1; LIRAGLUTIDE; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA 21; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; OBETICHOLIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; SYNDECAN 1; TRANSCRIPTION FACTOR NRF2; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN; FRUCTOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; VITAMIN D;

ADIPOSE TISSUE; APOPTOSIS; ATHEROGENIC DYSLIPIDEMIA; CELL ENERGY; CHRONIC KIDNEY DISEASE; DIETARY INTAKE; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOWN REGULATION; DRUG TARGETING; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; EPIDEMIOLOGICAL DATA; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; FIBROGENESIS; GENE EXPRESSION; HUMAN; INFLAMMATION; INTESTINE FLORA; KIDNEY TUBULE; LIPID METABOLISM; LIPOPROTEIN METABOLISM; LIVER; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; UPREGULATION; VITAMIN D DEFICIENCY; COMPLICATION; DIET; FATTY LIVER; FIBROSIS; GENETIC EPIGENESIS; GENETICS; KIDNEY FAILURE, CHRONIC; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR;

DIET; EPIGENESIS, GENETIC; FATTY LIVER; FIBROSIS; FRUCTOSE; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; LIPID METABOLISM; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; VITAMIN D;

EID: 84988944839     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-1182     Document Type: Review

References (137)

1. Mc Cullough K, Sharma P, Ali T, et al. Measuring the population burden of chronic kidney disease: A systematic literature review of the estimated prevalence of impaired kidney function. Nephrol Dial Transplant 2012;27:1812-1821
2. Palmer SC, Mavridis D, Navarese E, et al. Comparative efficacy and safety of blood pressurelowering agents in adults with diabetes and kidney disease: A network meta-analysis. Lancet 2015;385:2047-2056
3. Musso G, Gambino R, Tabibian JH, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: A systematic review and meta-analysis. PLoS Med 2014;11: E1001680
4. Stepanova M, de Avila L, Birerdinc A, et al. In female patients with non-alcoholic fatty liver disease (NAFLD) presence, of type 2 diabetes (DM) and chronic kidney disease (CKD) are independently associated with the risk of mortality. Hepatology 2015;62(Suppl.):2205
5. Singal AK, Salameh H, Kuo YF, Wiesner RH. Evolving frequency and outcomes of simultaneous liver kidney transplants based on liver disease etiology. Transplantation 2014;98: 216-221
6. Mikolasevic I, Racki S, Zaputovic L, Lukenda V, Sladoje-Martinovic B, Orlic L. Nonalcoholic fatty liver disease (NAFLD) and cardiovascular risk in renal transplant recipients. Kidney Blood Press Res 2014;39:308-314
7. Sugar and Sweeteners Team, Market and Trade Economics, Economic Research Service, US Department of Agriculture. US per capita caloric sweeteners estimated deliveries for domestic food and beverage use, by calendar year. Available at: Http://www.ers.usda.gov/dataproducts/ sugar-and-sweeteners-yearbooktables. aspx
8. Johnson RJ, Nakagawa T, Sanchez-Lozada LG, et al. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes 2013;62:3307-3315
9. Fan CY,Wang MX, Ge CX,Wang X, Li JM, Kong LD. Betaine supplementation protects against high-fructose-induced renal injury in rats. J Nutr Biochem 2014;25:353-362
10. Sanyal AJ, Harrison SA, Francque SM, et al. The hepatic and extrahepatic profile of resolution of steatohepatitis induced by GFT-505. Hepatology 2015;62:1252A
11. Musso G, CassaderM, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of randomised trials. Diabetologia 2012;55:885-904
12. Sarafidis PA, Stafylas PC, Georgianos PI, Saratzis AN, Lasaridis AN. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: A meta-analysis. Am J Kidney Dis 2010;55: 835-847
13. Kandasamy N, Ashokkumar N. Renoprotective effect of myricetin restrains dyslipidemia and renal mesangial cell proliferation by the suppression of sterol regulatory element binding proteins in an experimental model of diabetic nephropathy. Eur J Pharmacol 2014;743: 53-62
14. Chen Y, Zhao L, Li Q, et al. Inflammatory stress reduces the effectiveness of statins in the kidney by disrupting HMGCoA reductase feedback regulation. Nephrol Dial Transplant 2014;29:1864-1878
15. Trionfini P, Benigni A, Remuzzi G. MicroRNAs in kidney physiology and disease. Nat RevNephrol 2015;11:23-33
16. Li J, Wilson A, Gao X, et al. Coordinated regulation of dimethylarginine dimethylaminohydrolase-1 and cationic amino acid transporter-1 by farnesoid X receptor in mouse liver and kidney and its implication in the control of blood levels of asymmetric dimethylarginine. J Pharmacol Exp Ther 2009;331: 234-243
17. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al.; NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebocontrolled trial. Lancet 2015;385:956-965
18. Musso G, Gambino R, Cassader M. Emerging molecular targets for the treatment of nonalcoholic fatty liver disease. Annu Rev Med 2010;61:375-392
19. Li J, Pan Y, KanM, et al. Hepatoprotective effects of berberine on liver fibrosis via activation of AMPactivated protein kinase. Life Sci 2014;98:24-30
20. Soetikno V, Sari FR, Sukumaran V, et al. Curcumin decreases renal triglyceride accumulation through AMPK-SREBP signaling pathway in streptozotocin-induced type 1 diabetic rats. J Nutr Biochem 2013;24:796-802
21. Anavi S, Hahn-Obercyger M, Madar Z, Tirosh O. Mechanism for HIF-1 activation by cholesterol under normoxia: A redox signaling pathway for liver damage. Free Radic Biol Med 2014;71:61-69
22. Musso G, Cassader M, Olivetti C, Rosina F, Carbone G, Gambino R. Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obes Rev 2013;14:417-431
23. Kim YC, Guan KL. mTOR: A pharmacologic target for autophagy regulation. J Clin Invest 2015;125:25-32
24. Sapp V, Gaffney L, EauClaire SF, Matthews RP. Fructose leads to hepatic steatosis in zebrafish that is reversed by mechanistic target of rapamycin (mTOR) inhibition. Hepatology 2014;60: 1581-1592
25. Chen H, Zhu J, Liu Y, et al. Lipopolysaccharide induces chronic kidney injury and fibrosis through activation of mTOR signaling in macrophages. Am J Nephrol 2015;42:305-317
26. Calvier L, Martinez-Martinez E, Miana M, et al. The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Heart Fail 2015;3:59-67
27. Imamura S, Hirai K, Hirai A. The glucagonlike peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients. Tohoku J ExpMed 2013; 231:57-61
28. Bergenstal RM, Wysham C, Macconell L, et al.; DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial. Lancet 2010;376:431-439
29. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326
30. Musso G, Cassader M, Cohney S, Pinach S, Saba F, Gambino R. Emerging liver-kidney interactions in nonalcoholic fatty liver disease. Trends Mol Med 2015;21:645-662
31. Stanford KI, Wang L, Castagnola J, et al. Heparan sulfate 2-O-sulfotransferase is required for triglyceride-rich lipoprotein clearance. J Biol Chem 2010;285:286-294
32. Xu J, Lloyd DJ, Hale C, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009;58:250-259
33. Zingerman B, Herman-Edelstein M, Erman A, et al. Effect of acetazolamide on obesity-induced glomerular hyperfiltration: A randomized controlled trial. PLoS One 2015;10:e0137163
34. Hayashizaki-Someya Y, Kurosaki E, Takasu T, et al. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino aciddefined diet in rats. Eur J Pharmacol 2015;754: 19-24
35. Yokono M, Takasu T, Hayashizaki Y, et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol 2014;727:66-74
36. Ojima A, Matsui T, Nishino Y, Nakamura N, Yamagishi S. Empagliflozin, an inhibitor of sodiumglucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEsreceptor axis. Horm Metab Res 2015;47:686-692
37. Yetley EA. Assessing the vitamin D status of the US population. Am J Clin Nutr 2008;88: 558S-564S
38. Barchetta I, Carotti S, Labbadia G, et al. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: Relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology 2012;56:2180-2187
39. Beilfuss A, Sowa JP, Sydor S. Vitamin D counteracts fibrogenic TGF-b signalling in human hepatic stellate cells both receptor-dependently and independently. Gut 2015;64:791-799
40. Wang XX, Jiang T, Shen Y, et al. Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism. Am J Physiol Renal Physiol 2011; 300:F801-F810
41. Xu L, Wan X, Huang Z, et al. Impact of vitamin D on chronic kidney diseases in non-dialysis patients: A meta-analysis of randomized controlled trials. PLoS One 2013;8:e61387
42. Dasarathy J, Varghese R, Kalinina I, Lopez R, McCullough AJ. Hypovitaminosis D in NAFLD requires high dose supplementation to reverse deficiency. Hepatology 2015;62:1273A
43. Parikh A, Chase HS, Vernocchi L, Stern L. Vitamin D resistance in chronic kidney disease (CKD). BMC Nephrol 2014 19;15:47
44. Xu Y, Huang J, Xin W, et al. Lipid accumulation is ahead of epithelial-to-mesenchymal transition and therapeutic intervention by acetyl-CoA carboxylase 2 silence in diabetic nephropathy. Metabolism 2014;63:716-726
45. Xin W, Zhao X, Liu L, et al. Acetyl-CoA carboxylase 2 suppression rescues human proximal tubular cells from palmitic acid induced lipotoxicity via autophagy. Biochem Biophys Res Commun 2015;463:364-369
46. Herman-Edelstein M, Scherzer P, Tobar A, LeviM, Gafter U. Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy. J Lipid Res 2014;55:561-572
47. Souza-Mello V. Peroxisome proliferatoractivated receptors as targets to treat nonalcoholic fatty liver disease. World J Hepatol 2015;7:1012-1019
48. Pawlak M, Baugé E, Bourguet W, et al. The transrepressive activity of peroxisome proliferatoractivated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice. Hepatology 2014; 60:1593-1606
49. Zhou Y, Lin S, Zhang L, Li Y. Resveratrol prevents renal lipotoxicity in high-fat diet-treated mouse model through regulating PPAR - A pathway. Mol Cell Biochem 2016;411:143-150
50. Collino M, Benetti E, Rogazzo M, et al. Reversal of the deleterious effects of chronic dietary HFCS-55 intake by PPAR-d agonism correlates with impaired NLRP3 inflammasome activation. Biochem Pharmacol 2013;85:257-264
51. Lee EY, Kim GT, Hyun M, et al. Peroxisome proliferator-activated receptor-d activation ameliorates albuminuria by preventing nephrin loss and restoring podocyte integrity in type 2 diabetes. Nephrol Dial Transplant 2012;27: 4069-4079
52. Shashank R. Saroglitazar in diabetic dyslipidemia. Abstract 126-LB presented at the 75th Scientific Sessions of the American Diabetes Association, 5-9 June 2015, Boston, Massachusetts
53. Banshi D. To assess the effect of 4mg saroglitazar on patients of diabetes dyslipidemia with nonalcoholic fatty liver disease for 24 weeks. Abstract 712-P presented at the 75th Scientific Sessions of the American Diabetes Association, 5-9 June 2015, Boston, Massachusetts
54. Ruilope L, Hanefeld M, Lincoff AM, et al. Effects of the dual peroxisome proliferator-activated receptor-a/g agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: A Phase IIb, randomized study. BMC Nephrol 2014;15:180
55. Musso G, Gambino R, Cassader M. Cholesterol metabolism and the pathogenesis of nonalcoholic steatohepatitis. Prog Lipid Res 2013; 52:175-191
56. Hu Z, Ren L,Wang C, Liu B, Song G. Effect of chenodeoxycholic acid on fibrosis, inflammation and oxidative stress in kidney in high-fructosefed Wistar rats. Kidney Blood Press Res 2012;36: 85-97
57. Wang XX, Jiang T, Shen Y, et al. The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. Am J Physiol Renal Physiol 2009; 297:F1587-F1596
58. Gerhard GS, DiStefano JK. Micro RNAs in the development of non-alcoholic fatty liver disease. World J Hepatol 2015;7:226-234
59. Dattaroy D, Pourhoseini S, Das S, et al. Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2015;308:G298-G312
60. Gomez IG,MacKenna DA, Johnson BG, et al. Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulatingmetabolic pathways. J Clin Invest 2015;125:141-156
61. HsuWH, Chen TH, Lee BH, Hsu YW, Pan TM. Monascin and ankaflavin act as natural AMPK activators with PPARa agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice. Food ChemToxicol 2014;64:94-103
62. Musso G, Olivetti C, Cassader M, Gambino R. Obstructive sleep apnea-hypopnea syndrome and nonalcoholic fatty liver disease: Emerging evidence and mechanisms. Semin Liver Dis 2012;32:49-64
63. Shoji K, Tanaka T, Nangaku M. Role of hypoxia in progressive chronic kidney disease and implications for therapy. Curr Opin Nephrol Hypertens 2014;23:161-168
64. Luo R, Zhang W, Zhao C, et al. Elevated endothelial hypoxia-inducible factor-1a contributes to glomerular injury and promotes hypertensive chronic kidney disease. Hypertension 2015;66: 75-84
65. Xiao J, Jin C, Liu Z, et al. The design, synthesis, and biological evaluation of novel YC-1 derivatives as potent anti-hepatic fibrosis agents. Org Biomol Chem 2015;13:7257-7264
66. Nordquist L, Friederich-PerssonM, Fasching A, et al. Activation of hypoxia-inducible factors prevents diabetic nephropathy. J Am Soc Nephrol 2015;26:328-338
67. Xu Y, Liu L, Xin W, et al. The renoprotective role of autophagy activation in proximal tubular epithelial cells in diabetic nephropathy. J Diabetes Complications 2015;29:976-983
68. Jiang H, Westerterp M, Wang C, Zhu Y, Ai D. Macrophage mTORC1 disruption reduces inflammation and insulin resistance in obese mice. Diabetologia 2014;57:2393-2404
69. Wang L, Liu X, Nie J, et al. ALCAT1 controls mitochondrial etiology of fatty liver diseases, linking defective mitophagy to steatosis. Hepatology 2015;61:486-496
70. Torricelli C, Daveri E, Salvadori S, et al. Phosphorylation-independent mTORC1 inhibition by the autophagy inducer Rottlerin. Cancer Lett 2015;360:17-27
71. Kawarazaki Y, Ichijo H, Naguro I. Apoptosis signal-regulating kinase 1 as a therapeutic target. Expert Opin Ther Targets 2014;18:651-664
72. Yamamoto E, Dong YF, Kataoka K, et al. Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition. Hypertension 2008;52: 573-580
73. Tesch GH,Ma FY, Han Y, Liles JT, Breckenridge DG, Nikolic-Paterson DJ. ASK1 inhibitor halts progression of diabetic nephropathy in Nos3-deficient mice. Diabetes 2015;64:3903-3913
74. Tebay LE, Robertson H, Durant ST, et al. Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease. Free Radic Biol Med 2015;88:108-146
75. Shimozono R, Asaoka Y, Yoshizawa Y, et al. Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model. Mol Pharmacol 2013; 84:62-70
76. Choi BH, Kang KS, Kwak MK. Effect of redox modulating NRF2 activators on chronic kidney disease. Molecules 2014;19:12727-12759
77. de Zeeuw D, Akizawa T, Agarwal R, et al. Rationale and trial design of bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes: The occurrence of renal events (BEACON). Am J Nephrol 2013; 37:212-222
78. Kufareva I, Salanga CL, Handel TM. Chemokine and chemokine receptor structure and interactions: Implications for therapeutic strategies. Immunol Cell Biol 2015;93:372-383
79. Oh DY, Morinaga H, Talukdar S, Bae EJ, Olefsky JM. Increased macrophage migration into adipose tissue in obese mice. Diabetes 2012;61:346-354
80. Baeck C, Wei X, Bartneck M, et al. Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice. Hepatology 2014;59:1060-1072
81. Moreno JA, Moreno S, Rubio-Navarro A, et al. Targeting chemokines in proteinuriainduced renal disease. Expert Opin Ther Targets 2012;16:833-845
82. de Zeeuw D, Bekker P, Henkel E, et al. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: A randomised trial. Lancet Diabetes Endocrinol 2015;3:687-696
83. Pugliese G, Iacobini C, Pesce CM, Menini S. Galectin-3: An emerging all-out player in metabolic disorders and their complications. Glycobiology 2015;25:136-150
84. Iacobini C,Menini S, Ricci C, et al. Galectin-3 ablation protects mice from diet-induced NASH: A major scavenging role for galectin-3 in liver. J Hepatol 2011;54:975-983
85. Drechsler C, Delgado G, Wanner C, et al. Galectin-3, renal function, and clinical outcomes: Results from the LURIC and 4D studies. J Am Soc Nephrol 2015;26:2213-2221
86. Frenay AR, Yu L, van der Velde AR, et al. Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy. Am J Physiol Renal Physiol 2015;308:F500-F509
87. Traber PG, Chou H, Zomer E, et al. Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS One 2013;8:e75361
88. Pang J, Rhodes DH, Pini M, et al. Increased adiposity, dysregulated glucose metabolism and systemic inflammation in Galectin-3 KO mice. PLoS One 2013;8:e57915
89. Zhou SW, Zhang M, Zhu M. Liraglutide reduces lipid accumulation in steatotic L-02 cells by enhancing autophagy. Mol Med Rep 2014; 10:2351-2357
90. Hwang HJ, Jung TW, Kim BH, et al. A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPKdependent and JNK-dependent inhibition of LECT2 expression. Biochem Pharmacol 2015; 98:157-166
91. Armstrong MJ, Houlihan DD, Rowe IA, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: Individual patient data meta-analysis of the LEAD program. Aliment Pharmacol Ther 2013;37: 234-242
92. Armstrong MJ, Hull D, Guo K, et al. Glucagonlike peptide 1 decreases lipotoxicity in nonalcoholic steatohepatitis. J Hepatol 2016;64: 399-408
93. Skov J, Dejgaard A, Frøkiær J, et al. Glucagonlike peptide-1 (GLP-1): Effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab 2013;98: E664-E671
94. Zhang H, Zhang X, Hu C, Lu W. Exenatide reduces urinary transforming growth factor-b1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria. Kidney Blood Press Res 2012;35:483-488
95. Groop PH, Cooper ME, Perkovic V, Emser A, Woerle HJ, von Eynatten M. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 2013;36:3460-3468
96. Sanofi. Sanofi announces top-line results for cardiovascular outcomes study of Lyxumia- (lixisenatide), 2015. Available from http://www .news.sanofi.us/2015-03-19-Sanofi-Announces- Top-Line-Results-for-Cardiovascular-Outcomes- Study-of-Lyxumia-lixisenatide. Accessed 14 September 2015
97. Musso G, Gambino R, Cassader M. Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Annu Rev Med 2011;62:361-380
98. Wong J, Piceno YM, Desantis TZ, Pahl M, Andersen GL, Vaziri ND. Expansion of ureaseand uricase-containing, indole- and p-cresolforming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol 2014;39:230-237
99. Vaziri ND, Yuan J, Nazertehrani S, Ni Z, Liu S. Chronic kidney disease causes disruption of gastric and small intestinal epithelial tight junction. Am J Nephrol 2013;38:99-103
100. Adesso S, Popolo A, Bianco G, et al. The uremic toxin indoxyl sulphate enhances macrophage response to LPS. PLoS One 2013;8: E76778
101. Koppe L, Pillon NJ, Vella RE, et al. p-Cresyl sulfate promotes insulin resistance associated with CKD. J Am Soc Nephrol 2013;24:88-99
102. Wu IW, Hsu KH, Lee CC, et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant 2011;26:938-947
103. Nymark M, Pussinen PJ, Tuomainen AM, Forsblom C, Groop PH, Lehto M; FinnDiane Study Group. Serum lipopolysaccharide activity is associated with the progression of kidney disease in Finnish patients with type 1 diabetes. Diabetes Care 2009;32:1689-1693
104. Tang WH, Wang Z, Kennedy DJ, et al.; Gut Microbiota-Dependent Trimethylamine. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res 2015;116:448-455
105. Vaziri ND, Yuan J, Khazaeli M, Masuda Y, Ichii H, Liu S. Oral activated charcoal adsorbent (AST-120) ameliorates chronic kidney diseaseinduced intestinal epithelial barrier disruption. Am J Nephrol 2013;37:518-525
106. Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr 2014;99:535-542
107. Rossi M, Klein K, Johnson DW, Campbell KL. Pre-, pro-, and synbiotics: Do they have a role in reducing uremic toxins? A systematic review and meta-analysis. Int J Nephrol 2012;2012: 673631
108. Penno G, Solini A, Zoppini G, et al.; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Hypertriglyceridemia is independently associated with renal, but not retinal complications in subjects with type 2 diabetes: A cross-sectional analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. PLoS One 2015; 10:e0125512
109. Sonmez A, YilmazMI, SaglamM, et al. The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease. Lipids Health Dis 2015;14:29
110. Gyebi L, Soltani Z, Reisin E. Lipid nephrotoxicity: new concept for an old disease. Curr Hypertens Rep 2012;14:177-181
111. Wang Y, van der Tuin S, Tjeerdema N, et al. Plasma cholesteryl ester transfer protein is predominantly derived from Kupffer cells. Hepatology 2015;62:1710-1722
112. Liaw YW, Lin CY, Lai YS, et al. A vaccine targeted at CETP alleviates high fat and high cholesterol diet-induced atherosclerosis and non-alcoholic steatohepatitis in rabbit. PLoS One 2014;9:e111529
113. Deng Y, Foley EM, Gonzales JC, Gordts PL, Li Y, Esko JD. Shedding of syndecan-1 fromhuman hepatocytes alters very low density lipoprotein clearance. Hepatology 2012;55:277-286
114. Yilmaz Y, Eren F, Colak Y, Senates E, Celikel CA, Imeryuz N. Hepatic expression and serum levels of syndecan 1 (CD138) in patients with nonalcoholic fatty liver disease. Scand J Gastroenterol 2012;47:1488-1493
115. Okazaki I, Noro T, Tsutsui N, et al. Fibrogenesis and carcinogenesis in nonalcoholic steatohepatitis (NASH): Involvement of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinase (TIMPs). Cancers (Basel) 2014;6:1220-1255
116. Hardwick RN, Ferreira DW, More VR, et al. Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease. DrugMetab Dispos 2013;41:554-561
117. Adepu S, Katta K, Tietge UJ, et al. Hepatic syndecan-1 changes associatewith dyslipidemia after renal transplantation. Am J Transplant 2014;14:2328-2338
118. Padberg JS, Wiesinger A, di Marco GS, et al. Damage of the endothelial glycocalyx in chronic kidney disease. Atherosclerosis 2014; 234:335-343
119. Zeng Y, Adamson RH, Curry FR, Tarbell JM. Sphingosine-1-phosphate protects endothelial glycocalyx by inhibiting syndecan-1 shedding. Am J Physiol Heart Circ Physiol 2014;306:H363-H372
120. Zhang J, Li Y. Fibroblast growth factor 21 analogs for treating metabolic disorders. Front Endocrinol (Lausanne) 2015;6:168
121. Xu P, Zhang Y, Liu Y, et al. Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-b/smad2/3 and NF-kB signaling pathways. Toxicol Appl Pharmacol 2016;290: 43-53
122. Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor 21 (FGF21)- resistant state. Diabetes 2010;59:2781-2789
123. Gaich G, Chien JY, Fu H, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 2013; 18:333-340
124. Skrtić M, Yang GK, Perkins BA, et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia 2014;57:2599-2602
125. Elliott RH, Matthews VB, Rudnicka C, Schlaich MP. Is it time to think about the sodium glucose co-transporter 2 sympathetically?. Nephrology (Carlton) 2016;21:286-294
126. Panchapakesan U, Pegg K, Gross S, et al. Effects of SGLT2 inhibition in human kidney proximal tubular cellsdrenoprotection in diabetic nephropathy?. PLoS One 2013;8: E54442
127. Lambers Heerspink HJ, Johnsson E, Gause- Nilsson I, Johannson K, SjostromCD. Dapagliflozin reduces albuminuria on top of renin-angiotensin system blockade in hypertensive diabetic patients. Diabetes 2015;64:A303
128. Vallon V, Gerasimova M, Rose MA, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 2014;306:F194-F204
129. Yale JF, Bakris G, Cariou B, et al.; DIA3004 Study Group. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 2014;16:1016-1027
130. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128
131. Wilkison W, Cheatham B,Walker S. Remogliflozin etabonate reduces insulin resistance and liver function enzymes: Role for treatment of NASH. J Hepatology 2015;62(Suppl. 2): S211-S212
132. Fushimi N, Shibuya T, Takeishi S, Itou S, Kawai H, Mori A. Hepatic fat deposition is improved more with SGLT2 inhibitor luseogliflozin compared with sitagliptin: A randomised, crossover, controlled study using computed tomography. Diabetologia 2015;58(Suppl. 1):S392
133. Qiang S, Nakatsu Y, Seno Y, et al. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol Metab Syndr 2015;7:104
134. Cherney DZI, Perkins BA, Soleymanlou N, et al. Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Kidney Int 2014;86:1057-1058
135. Dransfeld O, Gehrmann T, Köhrer K, et al. Oligonucleotide microarray analysis of differential transporter regulation in the regenerating rat liver. Liver Int 2005;25:1243-1258
136. U.S. Food and Drug Administration. FDA drug safety communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in blood [Internet], 2015. Silver Spring, MD, U.S. Food and Drug Administration. Available from http://www .fda.gov/Drugs/DrugSafety/ucm446845.htm. Accessed 30 January 2016
137. Musso G, Cassader M, Gambino R. Nonalcoholic steatohepatitis: Emergingmolecular targets and therapeutic strategies. Nat Rev Drug Discov 2016;15:249-274